Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $128,044.80 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the transaction, the insider now owns 24,592 shares of the company’s stock, valued at approximately $546,680.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christine Ring also recently made the following trade(s):

• On Tuesday, September 3rd, Christine Ring sold 9,050 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.94, for a total value of $225,707.00.
• On Monday, August 26th, Christine Ring sold 9,870 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.01, for a total transaction of $246,848.70.
• On Thursday, August 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $21.43, for a total transaction of $123,436.80.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX traded down $0.38 during midday trading on Tuesday, hitting $22.09. The company had a trading volume of 888,452 shares, compared to its average volume of 890,862. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -7.57 and a beta of 2.23. The company has a fifty day moving average of $23.14 and a two-hundred day moving average of $18.78. Nurix Therapeutics, Inc. has a 12-month low of $4.22 and a 12-month high of $26.31.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million during the quarter, compared to the consensus estimate of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. Research analysts expect that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the subject of several recent analyst reports. Royal Bank of Canada boosted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. Oppenheimer raised their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. Robert W. Baird began coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 price objective for the company. Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, July 12th. Finally, HC Wainwright lifted their target price on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, June 18th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after purchasing an additional 3,424 shares during the period. EntryPoint Capital LLC purchased a new stake in Nurix Therapeutics in the 1st quarter worth $123,000. China Universal Asset Management Co. Ltd. raised its holdings in Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares during the period. Dark Forest Capital Management LP bought a new position in shares of Nurix Therapeutics in the second quarter worth about $201,000. Finally, ProShare Advisors LLC grew its position in shares of Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.